Apple
AAPL
Oracle
ORCL
Adobe
ADBE
Ecopetrol
EC
D.R. Horton
DHI
US Stock MarketDetailed Quotes
OCGN Ocugen
- 0.7545
- -0.0776-9.33%
Close Dec 18 16:00 ET
- 0.8099
- +0.0554+7.34%
Pre 06:59 ET
219.80MMarket Cap-3.97P/E (TTM)
0.8424High0.7417Low9.15MVolume0.8238Open0.8321Pre Close7.18MTurnover3.19%Turnover RatioLossP/E (Static)291.32MShares2.105052wk High5.43P/B216.79MFloat Cap0.457852wk Low--Dividend TTM287.33MShs Float778.1999Historical High--Div YieldTTM12.10%Amplitude0.1700Historical Low0.7840Avg Price1Lot Size
About Ocugen Company
Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.
Company Profile
SymbolOCGN
Company NameOcugen
Listing DateDec 3, 2014
Issue Price11.00
Founded2013
CEODr. Shankar Musunuri, M.B.A.,PhD
MarketNASDAQ
Employees65
Fiscal Year Ends12-31
Address11 Great Valley Parkway
CityMalvern
ProvincePennsylvania
CountryUnited States of America
Zip Code19355
Phone1-484-328-4701
Websitehttp://www.ocugen.com
Company Executives
- Name
- Position
- Salary
- Dr. Shankar Musunuri, M.B.A.,PhD
- Chairman of the Board and Chief Executive Officer
- 7.66M
- Ramesh Ramachandran
- Principal Financial Officer and Chief Accounting Officer
- --
- Dr. Huma Qamar, M.D.,PhD
- Chief Medical Officer
- --
- Arun Upadhyay, PhD
- Chief Scientific Officer and Head, Research, Development, and Medical
- --
- Dr. Junge Zhang, PhD
- Independent Director
- 335.56K
- Dr. Prabhavathi Fernandes, PhD
- Lead Independent Director
- 357.60K
- Dr. Marna C. Whittington, PhD
- Independent Director
- 649.56K
- Kirsten Castillo, M.B.A.
- Independent Director
- 348.18K
- Uday B. Kompella, PhD
- Independent Director
- 341.82K
- Michael Breininger, C.P.A.,M.B.A.
- Corporate Controller
- --
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.